Abstract

One of the indicators of the effectiveness of the pharmacovigilance system is the number and quality of spontaneous reports of cases of adverse reactions (AR). It is important to receive spontaneous reports from both medical and pharmaceutical workers and from drug users in order to assess the true nature of the adverse reaction. This article discusses the problems of a limited number of spontaneous reports from patients and low awareness of the population on the safety and effectiveness of drugs in the countries of the Eurasian Economic Union (EAEU). The aim of this article was to analyze the attitude of drug users to the submission of spontaneous reports of adverse reactions to medications. To achieve this aim, a sociological study was conducted based on a survey of drug users. The study involved 800 drug users. This study found that in the EAEU countries, patients face adverse reactions or lack of effectiveness of therapy, but unlike the Russian Federation, consumers of the Republics of Belarus, Armenia and the Kyrgyz Republic don’t report this information to state regulatory authorities, pharmacy organizations, or manufacturers of medicines. Less than 20% of respondents know about filling out a notice of an adverse reaction or lack of therapeutic effect of a drug on the Roszdravnadzor website. In our opinion, the involvement of drug users in the spontaneous reporting system has many advantages and can help solve the current problem of underestimating data on adverse reactions.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.